Norditropin Flexpro (Somatropin)

Somatropin, the active ingredient in Norditropin Flexpro, is a human growth hormone presented as a solution for injection for subcutaneous use. It treats growth hormone deficiency and related growth disorders in children and adults, supporting normal growth, metabolism, and body composition.

GNH USA supplies Norditropin Flexpro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable cold‑chain logistics for biologic products across diverse markets, with a focus on timely delivery and comprehensive documentation.

Norditropin Flexpro (somatropin) is employed in growth hormone therapy to address conditions caused by insufficient endogenous growth hormone.

- Growth hormone deficiency: promotes linear growth and improves metabolic parameters in children and adults with confirmed deficiency. - Turner syndrome: supports growth velocity and final adult height in girls with Turner syndrome. - Chronic renal insufficiency: helps improve growth in pediatric patients with renal failure. - Prader‑Willi syndrome: assists in increasing height and improving body composition in affected individuals. - Short stature due to being small for gestational age: enhances growth outcomes in children born SGA. - Idiopathic short stature: stimulates growth in children with unexplained short stature.

Somatropin may be associated with a spectrum of adverse reactions, ranging from mild to severe.

Common Side Effects: - Injection site pain or erythema - Headache - Joint stiffness or arthralgia - Swelling of hands, feet, or facial tissues

Serious or Rare Side Effects: - Intracranial hypertension - Slipped capital femoral epiphysis - Severe allergic reaction (anaphylaxis) - Abnormal glucose metabolism or new‑onset diabetes

When using Norditropin Flexpro, clinicians should observe specific precautions to optimise safety and therapeutic benefit.

Dose titration: adjust based on IGF‑1 levels and growth response Monitoring: regular assessment of glucose, thyroid function, and tumor markers Contraindications: not for patients with active malignancy Pregnancy and lactation: use only if clearly needed after risk‑benefit discussion with physician Pediatric use: monitor growth velocity and bone age closely Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake

Somatropin can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Glucocorticoids: may antagonize growth‑promoting effects - Insulin or oral hypoglycemics: increased risk of hypoglycemia - Estrogen therapy: may alter IGF‑1 response

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: may require dose adjustment - Anticonvulsants (e.g., phenobarbital): may increase somatropin clearance - Diuretics: may exacerbate peripheral edema